Guideline-Concordant Care Lower for Black Patients With CRC
Black patients who are newly diagnosed with colorectal cancer (CRC) receive worse and less-timely...
Read MoreJan 5, 2024
Black patients who are newly diagnosed with colorectal cancer (CRC) receive worse and less-timely...
Read MoreJan 5, 2024
Over time, young adults are moving away from combustible cigarettes to e-cigarettes, according to...
Read MoreJan 5, 2024
In a study comparing atezolizumab monotherapy with platinum-based chemotherapy in advanced...
Read MoreJan 5, 2024
1. In patients with mantle-cell lymphoma who responded to induction therapy and autologous stem...
Read MoreJan 4, 2024
The rate of new lung cancer cases has decreased, and survival has improved over the past 5 years,...
Read MoreJan 4, 2024
Researchers described a new familial lung cancer caused by an inherited mutation in EGFR in a...
Read MoreJan 4, 2024
The risk for developing breast cancer after a false-positive mammography result varies with age,...
Read MoreJan 4, 2024
For patients with early-stage breast cancer treated with neoadjuvant chemotherapy (NACT), Black...
Read MoreJan 4, 2024
In a clinical practice guideline published in Practical Radiation Oncology, the American Society...
Read MoreJan 3, 2024
Including additional risk factors improves the predictive value of the Breast Cancer Surveillance...
Read MoreDec 30, 2023
In a study comparing atezolizumab monotherapy with platinum-based chemotherapy in advanced...
Read MoreDec 29, 2023
1. Mirvetuximab soravtansine-gynx (MIRV) significantly improved progression-free survival,...
Read MoreDec 27, 2023
1. In this cross-sectional study, family caregivers of patients with advanced cancer had moderate...
Read MoreDec 26, 2023
1. In patients with mantle-cell lymphoma who responded to induction therapy and autologous stem...
Read MoreDec 26, 2023
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the...
Read MoreDec 19, 2023
1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival,...
Read MoreDec 19, 2023
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab...
Read MoreDec 19, 2023
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as...
Read MoreDec 13, 2023
1. In this cross-sectional study, having carrier status of actionable genes identified by the...
Read MoreDec 12, 2023
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related...
Read More